Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP shares were up 6.8% on Thursday . The company traded as high as $8.80 and last traded at $8.58. Approximately 1,037,987 shares traded hands during mid-day trading, a decline of 22% from the average daily volume of 1,333,423 shares. The stock had previously closed at $8.03.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.
Check Out Our Latest Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Performance
The company's 50 day moving average is $8.09 and its 200 day moving average is $8.16. The firm has a market cap of $1.17 billion, a P/E ratio of 23.35 and a beta of 1.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million for the quarter, compared to analysts' expectations of $61.06 million. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. As a group, equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.
Institutional Trading of Aurinia Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the business. Voya Investment Management LLC raised its stake in Aurinia Pharmaceuticals by 14.8% in the 1st quarter. Voya Investment Management LLC now owns 69,687 shares of the biotechnology company's stock valued at $560,000 after acquiring an additional 8,999 shares during the period. Strs Ohio purchased a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at $636,000. Teza Capital Management LLC purchased a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company's stock worth $642,000 after purchasing an additional 3,497 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Aurinia Pharmaceuticals by 2,299.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 317,656 shares of the biotechnology company's stock valued at $2,554,000 after acquiring an additional 304,420 shares in the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
